Active Ingredient: Olaparib
Olaparib in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, 300 milligrams olaparib, 2 times daily.
The recommended dose of olaparib is 300 mg taken twice daily, equivalent to a total daily dose of 600 mg.
When olaparib is used in combination with durvalumab for the maintenance treatment of patients with MMR-Proficient (pMMR) primary advanced or recurrent endometrial cancer whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel, the dose of durvalumab is 1500 mg every 4 weeks. Please refer to the full product information for durvalumab.
It is recommended that treatment be continued until progression of the underlying disease or unacceptable toxicity. Please refer to the product information for durvalumab.
If a patient misses a dose of olaparib, they should take their next normal dose at its scheduled time.
Treatment may be interrupted to manage adverse reactions such as nausea, vomiting, diarrhoea, and anaemia and dose reduction can be considered.
The recommended dose reduction is to 250 mg twice daily (equivalent to a total daily dose of 500 mg).
If a further dose reduction is required, then reduction to 200 mg twice daily (equivalent to a total daily dose of 400 mg) is recommended.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
